Two Directors at Next sold 57,588 shares at between 10,985p and 10,987p. The significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
EQS-News: ALLGEIER SE / Schlagwort(e): Stellungnahme Allgeier SE: Klarstellung zum Prüfungsergebnis der BaFin 11.03.2025 / 08:51 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. München, 11.03.2025 – Die Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) hat am gestrigen Tag das Ergebnis ihrer am 12. Juli 2022 angekündigten Prüfung betreffend den Konzernabschluss der Allgeier SE (ISIN DE000A2GS633, WKN A2GS63) zum 31. Dezember 2020 veröffentlicht. Der Vorstand der Allgeier SE möchte dazu folgendes erläutern und klarstellen: Die v...
EQS-News: ALLGEIER SE / Key word(s): Statement Allgeier SE: Clarification on the BaFin audit result 11.03.2025 / 08:51 CET/CEST The issuer is solely responsible for the content of this announcement. Munich, 11 March 2025 – Yesterday, the German Federal Financial Supervisory Authority (BaFin) published the results of its audit, announced on July 12, 2022, on the consolidated financial statements of Allgeier SE (ISIN DE000A2GS633, WKN A2GS63) as of December 31, 2020. With regard to this, the Management Board of Allgeier SE would like to explain and clarify the following: T...
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec gibt wichtige Fortschritte in der Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt 04.03.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Laufende strategische Partnerschaft bringt gemeinsame Pipeline in der Neurodegenerationsforschung voran Evotec erhält eine Zahlung von 20 Millionen Dollar, um die Forschung weiter voranzutreiben Hamburg, 04 März 2025: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: ...
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb 04.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research Hamburg, Germany, 04 March 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced another major accomplishment in it...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.